Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + Pivanex
- Development stage
- Discontinued
- Lead developer
- Titan Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
The combination of docetaxel and Pivanex is an investigational therapy for advanced non-small cell lung cancer (NSCLC). Docetaxel is a taxane chemotherapy agent that stabilizes microtubules, inhibiting cell division. Pivanex (pivaloyloxymethylbutyrate) is a histone deacetylase inhibitor that induces tumor cell differentiation and/or apoptosis. Preclinical studies have shown synergy between these agents in growth inhibition of NSCLC cell lines and improved survival in animal models. Clinical trials have demonstrated the combination to be well tolerated with promising activity in patients with advanced NSCLC[1][2][5].
- Other names
- docetaxel plus Pivanexdocetaxel and Pivanex
02
Targets
HDAC (HDAC family)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on docetaxel + Pivanex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + Pivanex.